FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152001500> ?p ?o ?g. }

• W2152001500 endingPage "33" @default.
• W2152001500 startingPage "33" @default.
• W2152001500 abstract "We describe an approach to produce an autologous therapeutic antitumor vaccine using hydroxyapatite (HA) for vaccinating cancer patients. The novel approach involved (1) the purification of part of the self-tumor antigens/ adjuvants using column chromatography with HA, (2) the employ of HA as a medium to attract antigen-presenting cells (APCs) to the vaccination site, and (3) the use of HA as a vector to present in vivo the tumor antigens and adjuvants to the patient's APCs. The vaccine was prepared using and combining HA particles, with at least 3 heat shock proteins (gp96 was one of them possibly with chaperoned proteins/peptides as shown in the slot blots) and with proteins from the cell membrane system (including Hsp70, Hsp27, and membrane proteins). The timing of HA degradation was tested in rats; the HA particles administered under the skin attracted macrophages and were degraded into smaller particles, and they were totally phagocytized within 1 week. In patients (n = 20), the vaccine was then administered weekly and showed very low toxicity, causing minor and tolerable local inflammation (erythema, papule, or local pain); only 1 patient who received a larger dose presented hot flashes, and there were no systemic manifestations of toxicity or autoimmune diseases attributed to the vaccine. Our study suggests that this therapeutic vaccine has shown some efficacy producing a positive response in certain patients. Stable disease was noted in 25% of the patients (renal carcinoma, breast carcinoma, and astrocytoma), and a partial response was noted in 15% of the patients (breast carcinoma and astrocytoma). The most encouraging results were seen in patients with recurrent disease; 4 patients in these conditions (20%) are disease free following the vaccine administration. However, we do not want to overstate the clinical efficacy in this small number of patients. The therapeutic vaccine tested in our study is working by activating the T-cell response as was shown in the comparative histological and immunohistochemical study performed in the pre- and postvaccine biopsy taken from a patient with inflammatory breast carcinoma. However, we cannot ruled out that the vaccine could also be producing an antibody(ies)-mediated response. In conclusion, this therapeutic vaccine based on HA ceramic particles and self-antigens can be safely administered and is showing some encouraging clinical results in cancer patients." @default.
• W2152001500 created "2016-06-24" @default.
• W2152001500 creator A5030460166 @default.
• W2152001500 creator A5032951976 @default.
• W2152001500 creator A5061724621 @default.
• W2152001500 date "2007-01-01" @default.
• W2152001500 modified "2023-09-27" @default.
• W2152001500 title "A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients" @default.
• W2152001500 cites W1950270470 @default.
• W2152001500 cites W1957293994 @default.
• W2152001500 cites W1969070933 @default.
• W2152001500 cites W1989660541 @default.
• W2152001500 cites W1991283648 @default.
• W2152001500 cites W1992699637 @default.
• W2152001500 cites W2006198332 @default.
• W2152001500 cites W2012951244 @default.
• W2152001500 cites W2027098270 @default.
• W2152001500 cites W2028804305 @default.
• W2152001500 cites W2035555277 @default.
• W2152001500 cites W2063956958 @default.
• W2152001500 cites W2064056040 @default.
• W2152001500 cites W2073616094 @default.
• W2152001500 cites W2074270635 @default.
• W2152001500 cites W2081194991 @default.
• W2152001500 cites W2084653384 @default.
• W2152001500 cites W2088335117 @default.
• W2152001500 cites W2089040209 @default.
• W2152001500 cites W2091262906 @default.
• W2152001500 cites W2098263349 @default.
• W2152001500 cites W2099735866 @default.
• W2152001500 cites W2106380556 @default.
• W2152001500 cites W2107008078 @default.
• W2152001500 cites W2116812203 @default.
• W2152001500 cites W2123745766 @default.
• W2152001500 cites W2125007784 @default.
• W2152001500 cites W2160584046 @default.
• W2152001500 cites W2160914593 @default.
• W2152001500 cites W2174651809 @default.
• W2152001500 cites W2185299261 @default.
• W2152001500 cites W2214565008 @default.
• W2152001500 cites W6389354 @default.
• W2152001500 cites W67767507 @default.
• W2152001500 doi "https://doi.org/10.1379/csc-218r.1" @default.
• W2152001500 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1852891" @default.
• W2152001500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17441505" @default.
• W2152001500 hasPublicationYear "2007" @default.
• W2152001500 type Work @default.
• W2152001500 sameAs 2152001500 @default.
• W2152001500 citedByCount "46" @default.
• W2152001500 countsByYear W21520015002012 @default.
• W2152001500 countsByYear W21520015002013 @default.
• W2152001500 countsByYear W21520015002014 @default.
• W2152001500 countsByYear W21520015002015 @default.
• W2152001500 countsByYear W21520015002016 @default.
• W2152001500 countsByYear W21520015002017 @default.
• W2152001500 countsByYear W21520015002018 @default.
• W2152001500 countsByYear W21520015002019 @default.
• W2152001500 countsByYear W21520015002020 @default.
• W2152001500 countsByYear W21520015002021 @default.
• W2152001500 countsByYear W21520015002022 @default.
• W2152001500 crossrefType "journal-article" @default.
• W2152001500 hasAuthorship W2152001500A5030460166 @default.
• W2152001500 hasAuthorship W2152001500A5032951976 @default.
• W2152001500 hasAuthorship W2152001500A5061724621 @default.
• W2152001500 hasBestOaLocation W21520015002 @default.
• W2152001500 hasConcept C104317684 @default.
• W2152001500 hasConcept C126322002 @default.
• W2152001500 hasConcept C147483822 @default.
• W2152001500 hasConcept C185592680 @default.
• W2152001500 hasConcept C203014093 @default.
• W2152001500 hasConcept C205260736 @default.
• W2152001500 hasConcept C2776624504 @default.
• W2152001500 hasConcept C2777701055 @default.
• W2152001500 hasConcept C2778378633 @default.
• W2152001500 hasConcept C2779121184 @default.
• W2152001500 hasConcept C29730261 @default.
• W2152001500 hasConcept C502942594 @default.
• W2152001500 hasConcept C55493867 @default.
• W2152001500 hasConcept C71924100 @default.
• W2152001500 hasConcept C8891405 @default.
• W2152001500 hasConceptScore W2152001500C104317684 @default.
• W2152001500 hasConceptScore W2152001500C126322002 @default.
• W2152001500 hasConceptScore W2152001500C147483822 @default.
• W2152001500 hasConceptScore W2152001500C185592680 @default.
• W2152001500 hasConceptScore W2152001500C203014093 @default.
• W2152001500 hasConceptScore W2152001500C205260736 @default.
• W2152001500 hasConceptScore W2152001500C2776624504 @default.
• W2152001500 hasConceptScore W2152001500C2777701055 @default.
• W2152001500 hasConceptScore W2152001500C2778378633 @default.
• W2152001500 hasConceptScore W2152001500C2779121184 @default.
• W2152001500 hasConceptScore W2152001500C29730261 @default.
• W2152001500 hasConceptScore W2152001500C502942594 @default.
• W2152001500 hasConceptScore W2152001500C55493867 @default.
• W2152001500 hasConceptScore W2152001500C71924100 @default.
• W2152001500 hasConceptScore W2152001500C8891405 @default.
• W2152001500 hasIssue "1" @default.
• W2152001500 hasLocation W21520015001 @default.
• W2152001500 hasLocation W21520015002 @default.

• next